PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



ADCs for Clinical Research in the Global Market .pdf


Original filename: ADCs for Clinical Research in the Global Market.pdf
Author: Administrator

This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 28/02/2020 at 03:04, from IP address 103.192.x.x. The current document download page has been viewed 23 times.
File size: 72 KB (4 pages).
Privacy: public file




Download original PDF file









Document preview


https://www.biochempeg.com

Biochempeg Scientific Inc.

ADCs for Clinical Research in the Global Market
With the FDA's successive approval of ADC at the end of last year, this class
of drugs has again become an obvious trend after a long period of time, which
has given people a little more confidence in many ADC projects under
development.
The following table counts 60 ADC projects under development in the global
market. (If there are any omissions, readers are welcome to add them.)

Project Name

Company

Target

Research Phase

Application

ImmunoGen

FRA

ph3

carcinoma of fallopian tube

Synthon

HER2/neu

Ph3

HER2/neu

ph3

Bayer

mesothelin

ph2

Genmab

CD142

ph2

RemeGen,Ltd.

HER2/neu

ph2

ADC Therapeutics

CD19

ph2

relapsed or refractory DLBCL

ADC Therapeutics

CD25

ph2

Hodgkin lymphoma

AbbVie

c-met

ph2

NSCLC

6SK

BCMA

ph2

Multiple myeloma

Roche

LIV1

Ph1/2

Triple Negative Breast Cancer(TNBC)

Daiichi Sankyo

HER3

Ph1/2

BMS-986148

BMS

mesothelin

Ph1/2

solid tumor

enapotamab

Seattle Genetics

AXL

Ph1/2

solid tumor

mirvetuximab
soravtansine
trastuzumab
duocarmazine
trastuzumab

Bio-Thera

maytansine

Solutions

anetumab
ravtansine
tisotumab
vedotin
Remegen RC48
loncsstuximab
tesirine
camidanlumab
tesirine
telisotuzumab
vedotin
belantamab
mafodotin
ladiratuzumab
vedotin
patritumab
deruxtecan

HER2 positive metastatic breast
cancer
HER2 positive metastatic breast
cancer
pancreatic cancer
ovarian cancer
HER2 positive metastatic breast
cancer

HER3 positive metastatic breast
cancer

https://www.biochempeg.com

Biochempeg Scientific Inc.

vedotin
solid tumor

BA3011

BioAtla

AXL

Ph1/2

CX-2029

CytomX

CD71

Ph1/2

HER2/neu

Ph1/2

HER2 Positive solid tumor
Metastatic solid tumor

A166

Kelun
Pharmaceutical

solid tumor

W0101

MSD

IGF-1R

Ph1/2

BA3021

BioAtla

ROR2

Ph1/2

TROP2

Ph1/2

Metastatic solid tumor
acute lymphatic leukaemia

SKB264

Kelun
Pharmaceutical

ADCT-602

ADC Therapeutics

CD22

Ph1/2

OBI-999

Obi Pharma

Globo H

Ph1/2

DS-7300a

Daiichi Sankyo

B7-H3

Ph1/2

MORAb-202

Morphotek

FRA

Ph1

TAK-164

Takeda

GCC

Ph1

ZW49

Zyme works

HER2/neu

Ph1

TR1801-ADC

Mitsubishi Tanabe

c-met

Ph1

STRO-002

Sutro

FRA

Ph1

JBH492

Novartis

CCR7

Ph1

DHES0815A

Roche

HER2/neu

Ph1

NJH395

Novartis

HER2/neu

Ph1

VLS-101

VelosBio

ROR1

Ph1

CD30

Ph1

F0002-ADC

Fudan-Zhangjiang
Bio-Pharmaceutical

FS-1502

Fosun Pharma

HER2/neu

Ph1

CC-99712

Celgene

BCMA

Ph1

AbGn-107

AbGenomics

C071

Ph1

SHR-A1201
SAR408701

Hengrui Medicine HER2/neu
Sanofi

CEACAM5

Ph1
Ph1/2

solid tumor

solid tumor
solid tumor
solid tumor
gastrointestinal cancer
HER2 Positive solid tumor
solid tumor
endometrial cancer
non-hodgkin lymphoma
HER2 positive metastatic breast
cancer
HER2 positive metastatic breast
cancer
haematological cancer
CD30-positive hematological
malignancies
HER2 positive metastatic breast
cancer
multiple myeloma
solid tumor
HER-2 positive recurrent metastatic
breast cancer
solid tumor

https://www.biochempeg.com

Biochempeg Scientific Inc.

AMG 224

Amgen

BCMA

Ph1/2

IMGN632

ImmunoGen

CD123

Ph1/2

STRO001

Sutro Biopharma

CD74

Ph1

Oncotherapy

FZD10

Ph1

HER2/neu

IgGl

PTK7

IgGl

tabituximab
barzuxetan

multiple myeloma
acute myelogenous leukemia
B-cell Lymphoma
synovialoma

Zhejiang
ARX788

Pharmaceutical

HER2 Positive solid tumor

,Ambrx
cofetuzumab

Pfizer,

pelidotin

StemCentRx

OBT076

Oxford Bio

CD205

IgGl

I6N002

ImmunGene

CD20

IgGl

AGS67E

Agensys, Astellas

CD37

Ph1

lymphoma

PCA062

Novartis

P-cadherin

Ph1

P-cadherin Positive solid tumor

MEDI3726

ADC Therapeutics

PSMA

Ph1

DS-1062a

Daiichi Sankyo

TTIOP2

Ph1

NSCLC

MEDI4276

Astrazeneca

HER2/neu

Ph1

HER2 Positive solid tumor

AGS62P1

Agensys, Astellas

FLT3

Ph1

acute lymphatic leukaemia

XMT-1522

Mersana

HER2/neu

Ph1

solid tumor

XMT-1536

Mersana

NaPi2b

Ph1

solid tumor

SHR-A1403

Hengrui Medicine

c.met

Ph1

solid tumor

MEDI7247

Astrazeneca

ASCT2

Ph1

haematological cancer

SYD1875

Synthon

TPBG

Ph1

solid tumor

Roche

CD79b

Ph1

non-hodgkin lymphoma

MEDI2228

Astrazeneca

BCMA

Ph1

TRPH-222

Triphase

CD22

Ph1

iladatuzumab
vedotin

triple-negative breast cancer(TNBC)
triple-negative breast cancer(TNBC)
non-hodgkin lymphoma

Prostate-specific membrane antigen
(PSMA)

multiple myeloma
B-cell Lymphoma

HER2 / neu can be described as one of the most classic targets in the history
of antibody drug development. Monoclonal antibodies against this target have
undergone many iterative updates. The development of derived bispecific
antibodies and ADC is also in full swing.
BCMA is the main target of multiple myeloma and competition is fierce. In
addition to the intra-field competition between many ADCs, there are external

https://www.biochempeg.com

Biochempeg Scientific Inc.

competitions from CAR-T cell therapy, and the market prospects are relatively
complex. From the perspective of cost alone, the odds of ADC drugs are
undoubtedly greater, but as a treatment method, clinical effect is the decisive
factor.
c-met is also a classic target. Roche invested in this target for a long time and
eventually failed. There may be many reasons, including c-met expression
profiles, antibody design problems, and so on. At present, there are two
mainstream R & D strategies for c-met: one is ADC, and the other is c-met /
EGFR bispecific antibody. There are also some research institutions trying to
use CAR-T treatment.


Of course, there are also many innovative targets on the pipeline, such as
TROP2, AXL, etc. It is expected that the potential of these targets can be fully
demonstrated, providing more options for clinical treatment.
Related Article:
Cleavable vs. Non-Cleavable Linkers in Antibody-Drug Conjugates
ADCs Against Cancer: Clinical Landscape and Challenges
History and Development of Antibody Drug Conjugates (ADCs)
Anti-Cancer ADC Drugs: 3 Design Elements, 7 Approved ADCs, Multiple
Clinical Trials


ADCs for Clinical Research in the Global Market.pdf - page 1/4
ADCs for Clinical Research in the Global Market.pdf - page 2/4
ADCs for Clinical Research in the Global Market.pdf - page 3/4
ADCs for Clinical Research in the Global Market.pdf - page 4/4

Related documents


untitled pdf document
cleavable vs non cleavable linkers in antibody drug conjugates
v15n4s57revisiting
ash 2011 bystander vaccine poster
jdit 2014 1007 004
marchettipaolo


Related keywords